Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.
about
Human engineered heart tissue as a versatile tool in basic research and preclinical toxicologyQTc interval screening for cardiac risk in methadone treatment of opioid dependenceThe regulation of the cardiac potassium channel (HERG) by caveolin-1Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1Antagonist action of progesterone at σ-receptors in the modulation of voltage-gated sodium channelsQT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy.Top-down, Bottom-up and Middle-out Strategies for Drug Cardiac Safety Assessment via Modeling and SimulationsRecent developments in using mechanistic cardiac modelling for drug safety evaluationRisk assessment of drug-induced QT prolongationNitric Oxide Synthase 1 Adaptor Protein, an Emerging New Genetic Marker for QT Prolongation and Sudden Cardiac DeathComputer-based prediction of the drug proarrhythmic effect: problems, issues, known and suspected challengesSex differences in the mechanisms underlying long QT syndromeInduced pluripotent stem cells as a disease modeling and drug screening platformThe anti-addiction drug ibogaine and the heart: a delicate relationClinical Potentials of Cardiomyocytes Derived from Patient-Specific Induced Pluripotent Stem CellsA novel 3D label-free monitoring system of hES-derived cardiomyocyte clusters: a step forward to in vitro cardiotoxicity testingOptoDyCE as an automated system for high-throughput all-optical dynamic cardiac electrophysiology.Optimisation of embryonic and larval ECG measurement in zebrafish for quantifying the effect of QT prolonging drugsScreening system for drug-induced arrhythmogenic risk combining a patch clamp and heart simulator.Drug-drug interactions and QT prolongation as a commonly assessed cardiac effect - comprehensive overview of clinical trialsEvaluation of drug-induced QT interval prolongation in animal and human studies: a literature review of concordanceBis(monoacylglycerol)phosphate as a non-invasive biomarker to monitor the onset and time-course of phospholipidosis with drug-induced toxicitiesElectrocardiographic Biomarkers for Detection of Drug-Induced Late Sodium Current BlockMarkov models of use-dependence and reverse use-dependence during the mouse cardiac action potentialDynamic link between histone H3 acetylation and an increase in the functional characteristics of human ESC/iPSC-derived cardiomyocytesCardiomyocyte MEA data analysis (CardioMDA)--a novel field potential data analysis software for pluripotent stem cell derived cardiomyocytesIntegrated analysis of drug-induced gene expression profiles predicts novel hERG inhibitorsPronounced effects of HERG-blockers E-4031 and erythromycin on APD, spatial APD dispersion and triangulation in transgenic long-QT type 1 rabbitsFrom linked open data to molecular interaction: studying selectivity trends for ligands of the human serotonin and dopamine transporterPrediction of Thorough QT study results using action potential simulations based on ion channel screensSudden death associated with QT interval prolongation and KCNQ1 gene mutation in a family of English Springer Spaniels.Efficient simulation of cardiac electrical propagation using high order finite elements.Molecular determinants of interactions between the N-terminal domain and the transmembrane core that modulate hERG K+ channel gating.Drug- and non-drug-associated QT interval prolongation.Screening drug-induced arrhythmia [corrected] using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays.Human iPSC-based cardiac microphysiological system for drug screening applications.Comparison of electrophysiological data from human-induced pluripotent stem cell-derived cardiomyocytes to functional preclinical safety assays.UNC1062, a new and potent Mer inhibitor.Predicting QTc Prolongation in Man From Only In Vitro Data.Early assessment of proarrhythmic risk of drugs using the in vitro data and single-cell-based in silico models: proof of concept.
P2860
Q21134989-161A396F-0F90-4F0B-9621-2044E8719773Q24201880-4B5E1DDB-0E41-457A-A359-A3539E2B60A3Q24324091-FE0F3273-2E7E-4D32-B51A-5B43FF3ED981Q24534620-0FA80775-D942-4A45-9A41-482C972D067FQ24616403-6517D4E6-C7F9-492B-AD45-C2BB97D22972Q24796217-9D079C44-A34F-4BBA-B49A-BF3D9F380F2FQ26739743-C3FE76D5-DB13-414E-AF3B-2379E7CE6195Q26764870-22AFCE70-B837-44D7-892A-6B22272F01B7Q26773356-F09DFF98-901F-4A03-9DA1-8947D8029922Q26859562-2B786AB0-8906-49CB-9766-950F91C11E2FQ26861453-449E0E24-9E22-44EA-AA99-97AC96B74491Q26862667-0F23A1BE-23D1-47CA-AC22-A159DEA826FCQ26865689-45A515C6-F0DF-4811-8A25-5121B4192FA8Q27009689-DA458D30-4EF7-4208-B02A-644005574575Q27021919-8ECBC5FA-AD4A-426A-872D-DA4CFBE0B0D7Q27311346-796239A5-C7EB-4EEF-9243-EFA15B05B341Q27317028-A2B2F4DE-3597-4656-B854-DE42D2B03677Q27330065-43D539F5-F3C5-4776-97FB-5CCC4CA324F2Q27343160-558D218C-EBD0-4135-80FF-F12B249CFFF9Q28071256-8955D4EE-E50F-40F8-A812-B2AC331A1C2AQ28083604-C880EACC-BC18-4057-BB57-A200C98777EBQ28278771-2724ED66-8BBF-47BD-AFDD-BCB99A184A16Q28468470-7816D1A4-9306-4CC5-8726-680D82AE7363Q28482100-E8814138-83AD-4F66-A243-9F449783572CQ28483678-02DAFB6B-50A8-41DE-8168-4AF45F08A0DEQ28533644-D872BAF7-5F26-4DE0-A1CE-FD4CCAED2094Q28534789-8075C611-E1D8-4C43-B232-A9C804CDAB72Q28543123-7D48A8F3-575A-4C6B-B381-8EC6A63B6D84Q28596136-F075062E-1DC8-4141-8DF4-A77ADC219CF2Q28649794-1A00F609-6E4A-46E9-BEFE-79CD502EEA69Q30372781-27F60C96-046B-42FF-A5F7-E38DF820CDB9Q30436088-33B27A2A-CFBA-4379-8251-C1C617C4DED7Q30474096-2E0996FA-830D-4A20-8507-29BB47C86D65Q30474909-2C71C374-B871-4DFC-8E08-E99F1F5F73BCQ30558954-E831FA0C-1AF8-4B17-9351-6864484FF6F2Q30625616-1AC7203C-A0FC-4539-AAC4-F958E441C97DQ30629611-B0B0C27A-5144-4900-A4CE-723CEBA1BD26Q30630130-675A4C04-DE7B-490D-AA68-07AF54059EDDQ30843780-952BA780-00E4-4CBF-8A35-83B1AFEA6597Q31140927-056B7363-FF4C-4E61-80EF-C42B388C6F9F
P2860
Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.
description
2003 nî lūn-bûn
@nan
2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Relationships between preclini ...... ty margin in drug development.
@ast
Relationships between preclini ...... ty margin in drug development.
@en
type
label
Relationships between preclini ...... ty margin in drug development.
@ast
Relationships between preclini ...... ty margin in drug development.
@en
prefLabel
Relationships between preclini ...... ty margin in drug development.
@ast
Relationships between preclini ...... ty margin in drug development.
@en
P2093
P1476
Relationships between preclini ...... ty margin in drug development.
@en
P2093
A T Sullivan
I MacKenzie
L Carlsson
P K S Siegl
S Palethorpe
T G Hammond
P356
10.1016/S0008-6363(02)00846-5
P577
2003-04-01T00:00:00Z